Impact of the 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of Streptococcus pneumoniae Among Children Attending Group Daycare in Southeastern France

Dunais, Brigitte; Bruno, Pascale; Touboul, P; Degand, Nicolas; Sakarovitch, Charlotte; Fontas, Éric; Haas, H.; Girard-Pipau, F.; Ruimy, Raymond; Pradier, Christian

doi:10.1097/inf.0000000000000559

Cited by 26 publications

(24 citation statements)

References 9 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In reference to serotypes identified, a high proportion (76.8%) of NVT was found among carriers as previously reported [ 17 , 18 , 30 , 32 ]. Almost 50% of NP carriage was due to five serotypes, namely 23A/B, 6C and 15A/B ( Fig 1 ) as described by others [ 17 , 31 ]. Conversely to the above studies, serotypes 35B/F were less prevalent while we had no NP carriage by 11A.…”

Section: Discussionsupporting

confidence: 81%

“…Fifteen children carried serotype 19A, two of which were fully vaccinated with PCV13. A recent study, evaluating the impact of PCV13 on NP carriage revealed that serotype 19A was the only persistent VT in the study population [ 17 ]. Lee et al found that the implementation of PCV13 in children 6–23 months of age in Massachusetts between 2007 and 2011 resulted in increased colonization with non-PCV13 serotypes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines

et al. 2016

View full text Add to dashboard Cite

The objective of the study was to describe the incidence of pneumococcal nasopharyngeal carriage, serotype distribution and antibiotic resistance profile of pneumococcal nasopharyngeal isolates in healthy children aged 6 to 36 months following the implementation of conjugate vaccines. A nasopharyngeal swab was collected from 1105 healthy children following a stratified random sampling between September 2013 and April 2014. Demographics, vaccination status and data on possible risk factors were recorded. Isolates were serotyped and tested for antibiotic susceptibility. The nasopharyngeal carriage rate was 25.3%. Among 1105 children enrolled, 393 had received PCV13 and 685 PCV10. The prevailing isolated serotypes were: 23A (14.3%), 15A (8.9%), 6C (8.6%), 23B (7.5%), 19A (5.4%) and 15B (5%). The proportion of non-vaccine serotypes, PCV10 serotypes, PCV13 additional serotypes (3, 6A, 19A) was 76.8%, 2.1% and 10.4% respectively. Although children, who were fully or partially vaccinated with PCV13, were 63% less likely to be colonized with additional PCV13 serotypes compared to those vaccinated with PCV10, the difference is not significant (95%Cl = 0.14–1.02, p = 0.053). The highest antibiotic non-susceptible rates were found for erythromycin (28.2%) and penicillin (27.9%). The overall multidrug resistance rate was 13.2%, with serotypes 24F (4/6), 15A (14/25) and 19A (6/15) being the main contributors. Carriage rate was similar between children vaccinated with PCV10 or PCV13. The high incidence of 15A serotype which is also multidrug resistant should be underlined. Ongoing surveillance is needed to monitor the dynamics on nasopharyngeal carriage.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines

et al. 2016

View full text Add to dashboard Cite

show abstract

“…13 However, while vaccine-type carriage has declined, VT pneumococci continue to be identified in 6% of children <5 years and 8% of infants in Kilifi, compared to <1-2% in other countries that use PCVs. [31][32][33][34][35] This may reflect a higher force of infection in Kilifi and it indicates continued risk for VT-IPD in unvaccinated or undervaccinated children, and adults. 36 An alternative explanation for the persistence of VT carriage in Kilifi is that, unlike most middle-income and high-income countries, Kenya introduced PCV10 without a booster dose in the second year of life.…”

Section: Discussionmentioning

confidence: 99%

Impact of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya

Hammitt

Etyang

Morpeth

et al. 2018

Preprint

View full text Add to dashboard Cite

Background: 10-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10 and 14 weeks of age, was introduced in Kenya in January 2011, accompanied by a catch-up campaign in Kilifi County for children <5 years. Coverage with ≥2 PCV10 doses in children 2-11 months was 80% in 2011 and 84% in 2016; coverage with ≥1 dose in children 12-59 months was 66% and 87%, respectively. Methods: Clinical and microbiological surveillance for invasive pneumococcal disease (IPD) among admissions of all ages at Kilifi County Hospital was linked to the Kilifi Health and Demographic Surveillance System from 1999-2016. We calculated the incidence rate ratio (IRR) comparing the pre-vaccine and postvaccine eras, adjusted for confounding, and reported percent reduction in IPD as 1-IRR. Annual crosssectional surveys of nasopharyngeal carriage were conducted from 2009-2016.Findings: Surveillance identified 667 IPD cases in 3,211,403 person-years of observation. IPD incidence in children <5 years fell sharply in 2011 following PCV10 introduction, and remained low (PCV10-type IPD: 60·8 vs 3·2/100,000 [92% reduction; 95%CI: 78, 97]; overall IPD: 81·6 vs 15·3/100,000 [68% reduction; 95%CI: 40, 83]; 1999-2010 vs 2012-2016. PCV10-type IPD also declined significantly in unvaccinated age groups (<2 months, 5-14 years, ≥15 years), with estimated reductions of 100%, 74%, and 81%, respectively. There was no significant change in the incidence of non-PCV10 type IPD. In children aged <5 years, PCV10-type carriage declined by 74% and non-PCV10-type carriage increased by 71%.

show abstract

“…31 Similarly, 3 years following the introduction of PCV13, Dunais showed that non-PCV13 strains accounted for 94% of nasopharyngeal carriage among healthy French children, with 15B/C and 35B among the most commonly identified types. 23 A recent US study showed 15% and 14% of pneumococcal isolates from the nasopharynx of 656 children in Atlanta were 35B and 15B/C, respectively. 35 Serotypes 35B and 15B/C have also been identified as increasing causes of IPD.…”

Section: Discussionmentioning

confidence: 99%

“…22 Similarly, carriage in French children decreased from 54% to 46% in a 3 year span. 23 In this work, we characterized pneumococcal nasopharyngeal carriage rates in HIV-infected adults following the introduction of PCV13 to the universal pediatric immunization schedule. In addition, we describe the serotype distribution and antibiotic susceptibility pattern for each of the isolates.…”

Section: Introductionmentioning

confidence: 99%

Nasopharyngeal pneumococcal carriage rates among HIV-infected adults following widespread pediatric use of conjugate pneumococcal vaccine-13

Feola

Bonville

Cibula

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Nasopharyngeal pneumococcal carriage rates among HIV-infected adults has not been described since conjugate pneumococcal vaccine-13 (PCV13) was added to the universal infant and childhood vaccination schedule in 2010. Methods: HIV-infected adults presenting for routine health care visits to the Designated AIDS Center in Syracuse, NY between December 2013 and June 2015 were eligible for enrollment. Demographic, medical, and social history were recorded after obtaining informed consent. Nasopharyngeal samples were collected and cultured for the presence of Streptococcus pneumoniae using standard microbiologic techniques. Antibiotic susceptibility testing was performed using E-test!. Results: 707 nasopharyngeal samples were collected from 414 HIV-infected adults. 18 samples were culture positive for S. pneumoniae; 1 (6%) isolate was of vaccine-type, 9 (50%) were non-vaccine types, and 8 (44%) were non-typeable. The 18 isolates were recovered from 15 different patients (4% of those enrolled). Three patients were culture positive for pneumococcus isolated from 2 consecutive samples, with non-typeable pneumococci identified consecutively from 2 patients and serotype 35B identified consecutively from 1 patient. The most commonly identified non-vaccine serotypes were 35B and 15B/C. Identified pneumococci were penicillin and cefotaxime susceptible. Conclusion: Four percent of HIVinfected adults in our study population were colonized with S. pneumoniae. The non-vaccine serotypes 35B and 15B/C predominated.

show abstract

Impact of the 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of Streptococcus pneumoniae Among Children Attending Group Daycare in Southeastern France

Cited by 26 publications

References 9 publications

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines

Impact of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya

Nasopharyngeal pneumococcal carriage rates among HIV-infected adults following widespread pediatric use of conjugate pneumococcal vaccine-13

Contact Info

Product

Resources

About